Company Monitoring Page for Astellas

latest headlines for company on cafepharma

Astellas inks biomarker deal to pinpoint Xtandi patients
BioPharma Dive
Sat, 02/4/17 - 09:59 am
Tags:
Astellas, Xtandi, biomarkers, patients, tumor profiles
Astellas boosts pharma's rep with corporate branding push
Medical Marketing and Media
Tue, 11/1/16 - 09:51 am
Tags:
Astellas, reputation, corporate branding
Astellas furthers oncology focus with Ganymed buy
BioPharma Dive
Fri, 10/28/16 - 05:48 pm
Tags:
Astellas, oncology, Ganymed, M&A, IMAB362, gastroesophageal cancer
Congress just fired a shot against its next drug-pricing target, and its shares took a hit
Yahoo/Business Insider
Mon, 03/28/16 - 09:10 pm
Tags:
US Congress, drug pricing, Medivation, Astellas, Xtandi
Astellas finally wraps up its $379M deal for Ocata
Fierce Biotech
Wed, 02/10/16 - 10:52 am
Tags:
Astellas, Ocata Therapeutics, M&A
Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Yahoo
Fri, 01/22/16 - 10:07 am
Tags:
Astellas, Ocata Therapeutics, M&A
After shareholder revolt, Astellas says it needs more time for proposed buyout of Ocata
Bizjournals.com
Fri, 12/18/15 - 09:01 am
Tags:
Astellas, Ocata Therapeutics, M&A, shareholders
Ocata investors scramble to nix Astellas' $379M buyout at the 11th hour
Fierce Biotech
Tue, 12/15/15 - 04:23 pm
Tags:
Astellas, M&A, Ocata Therapeutics
Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat
Fierce Pharma Marketing
Wed, 11/11/15 - 09:10 pm
Tags:
Medivation, Xtandi, hirings, Astellas
Astellas to Acquire Ocata Therapeutics
Yahoo
Tue, 11/10/15 - 08:36 am
Tags:
Astellas, Ocata Therapeutics, M&A, ophthalmology
4 Blockbuster Drugs Whose Sales Could Easily Double
Motley Fool
Mon, 10/26/15 - 08:46 am
Tags:
Xtandi, Medivation, Astellas, Eliquis, Pfizer, Bristol-Myers Squibb, Revlimid, Celgene, Invokana, JNJ
District Court Rules for FDA in Battle Over the Scope of 3-Year Exclusivity in the Context of Dueling Tacrolimus NDAs
FDA Law Blog
Wed, 06/17/15 - 06:36 pm
Tags:
FDA, exclusivity, Astellas, Veloxis, kidney transplants, Envarsus
Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use
Fierce Pharma Marketing
Wed, 06/17/15 - 10:24 am
Tags:
Astellas, Medivation, Xtandi, drug marketing, prostate cancer
Astellas wagers $760M to launch an autoimmune biotech in Cambridge, MA
Fierce Biotech
Wed, 06/3/15 - 11:12 am
Tags:
Astellas, autoimmune disease, Kanyos Bio, Anokion
Medivation's Xtandi sales fell short in Q1, but analysts say it's gaining on J&J's Zytiga
Fierce Pharma Marketing
Wed, 05/20/15 - 06:15 pm
Tags:
Medivation, Xtandi, Astellas, JNJ, Zytiga
Medivation's Xtandi Beats Casodex In Cancer Trial
Investors.com
Fri, 04/3/15 - 08:38 am
Tags:
Medivation, Xtandi, Casodex, Astellas, prostate cancer
11 promising drugs poised to be the next billion-dollar blockbusters
Yahoo/Business Insider
Sat, 03/28/15 - 10:26 am
Tags:
Opdivo, Praluent, LCZ696, lumacaftor, Viekira Pak, evolocumab, Gardasil 9, brexpiprazole, Toujeo, Cosentyx, Bristol-Myers Squibb, Regeneron, Sanofi, Novartis, Pfizer, AbbVie, Amge, Astellas, Merck, Otsuka, Lundbeck, Vertex Pharmaceuticals
Why 2015 is the year of the biopharma blockbuster—with charts
BioPharma Dive
Tue, 03/24/15 - 10:29 am
Tags:
biotech, Opdivo, Praluent, LCZ696, Ibrance, Viekira Pak, evolocumab, Gardasil 9, Bristol-Myers Squibb, Regeneron, Sanofi, Novartis, Pfizer, Vertex Pharmaceuticals, Merck, Amgen, AbbVie, Astellas
Astellas bags FDA approval for a new anti-infective
Fierce Biotech
Fri, 03/6/15 - 03:05 pm
Tags:
Astellas, FDA, antifungals, Cresemba
Astellas bets on Immunomic's allergy vaccine in a $75M deal
Fierce Biotech
Fri, 01/30/15 - 08:03 am
Tags:
Astellas, Immunomic, vaccines, LAMPs, allergies

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.